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RESEARCH ARTICLE

Open Access

LPA, HGF, and EGF utilize distinct combinations
of signaling pathways to promote migration and
invasion of MDA-MB-231 breast carcinoma cells
Susan MW Harrison1, Teresa Knifley1,2, Min Chen1,3 and Kathleen L O’Connor1,2*

Abstract
Background: Various pathways impinge on the actin-myosin pathway to facilitate cell migration and invasion
including members of the Rho family of small GTPases and MAPK. However, the signaling components that are
considered important for these processes vary substantially within the literature with certain pathways being
favored. These distinctions in signaling pathways utilized are often attributed to differences in cell type or
physiological conditions; however, these attributes have not been systematically assessed.
Methods: To address this question, we analyzed the migration and invasion of MDA-MB-231 breast carcinoma cell
line in response to various stimuli including lysophosphatidic acid (LPA), hepatocyte growth factor (HGF) and
epidermal growth factor (EGF) and determined the involvement of select signaling pathways that impact myosin
light chain phosphorylation.
Results: LPA, a potent stimulator of the Rho-ROCK pathway, surprisingly did not require the Rho-ROCK pathway to
stimulate migration but instead utilized Rac and MAPK. In contrast, LPA-stimulated invasion required Rho, Rac, and
MAPK. Of these three major pathways, EGF-stimulated MDA-MB-231 migration and invasion required Rho; however,
Rac was essential only for invasion and MAPK was dispensable for migration. HGF signaling, interestingly, utilized
the same pathways for migration and invasion, requiring Rho but not Rac signaling. Notably, the dependency of
HGF-stimulated migration and invasion as well as EGF-stimulated invasion on MAPK was subject to the inhibitors
used. As expected, myosin light chain kinase (MLCK), a convergence point for MAPK and Rho family GTPase
signaling, was required for all six conditions.
Conclusions: These observations suggest that, while multiple signaling pathways contribute to cancer cell motility,
not all pathways operate under all conditions. Thus, our study highlights the plasticity of cancer cells to adapt to
multiple migratory cues.
Keywords: Rho GTPases, RhoA, RhoC, ROCK, Rac1, MAPK, MLCK, Breast carcinoma, Chemotaxis, Invasion

Background
The motility of a cell is determined by its ability to coordinately regulate a dynamic organization of the cytoskeletal
architecture to create polarity, rigidity and contractile
forces necessary for movement. At the core of a cell’s ability to migrate is the interaction between actin and nonmuscle myosin II, whose activation states cycle in a
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systematically regulated manner (reviewed in [1,2]). Actin
polymerizes and depolymerizes on a continuous basis and
typically forms a meshwork with protrusions at the leading edge of the cell, pushing the plasma membrane
forward. At the rear of the cell, long, unbranched
actin-myosin filaments mediate contraction that pulls
the rear of the cell forward and retraction of the trailing edge to facilitate cell polarization that promotes
directed cell migration. During these coordinated processes, myosin II and its regulatory myosin light chain
(MLC) undergo cycles of phosphorylation and dephosphorylation; these changes affect the conformational state
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of myosin, allow it to interact with actin, and move actin
fibers relative to each other. In concert with the directed
polymerization of actin, the motor activity of myosin results in cell propulsion.
Numerous well-studied signal transduction pathways
converge to control the activity of actin and myosin II
(Figure 1) and, hence, cytoskeletal architecture and movement. Among the most influential are the Rho GTPases,
Rho and Rac (reviewed in [3,4]) but also include the MEK/
Erk mitogen-activated protein kinase (MAPK) pathway [5].
Rho promotes both actin polymerization and myosin II
contractility. Rho-induced actin polymerization is mediated
by the Rho effector mammalian homologue of diaphanous
(mDia) [6], a member of the formin family, while myosin II
activity is promoted through Rho-associated coiled coil
kinase (ROCK) control of myosin by inhibiting myosin
phosphatase [7,8]. Preventing myosin phosphatase from
dephosphorylating MLC prolongs MLC and thus myosin
activity. Rac, on the other hand, can inhibit myosin light
chain kinase (MLCK) to reduce myosin II activity while
simultaneously promoting actin polymerization; both of
these functions can be attributed to p21-activated kinases
(PAK) [9,10]. Recently, PAK was shown to be central to
the flow of actin in the lamella and the localization of myosin II at the leading edge to facilitate cell migration [11].
The Rho and Rac pathways converge on LIM-kinase
(LIMK) downstream of ROCK [12] and PAK [13], respectively, which leads to the phosphorylation and inactivation
of the F-actin depolymerizing protein cofilin, thereby stabilizing actin filaments [14]. MAPK has been shown to
limit activation of LIMK, subsequent phosphorylation of
cofilin, and migration of primary human T cells in a threedimensional (3D) environment [15]. The MAPK cascade
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Figure 1 Signaling pathways important for the control of actin
dynamics and myosin activity. Key signaling pathways that
converge on actin and myosin to control cell motility are depicted
and include Rho, Rac, MLCK, MAPK/MEK. The inhibitors for each of
these pathways used in this study are indicated in italics.

also regulates myosin II activity by phosphorylating and
enhancing the activity of MLCK [16]. Therefore, control
of actomyosin dynamics results from cooperation of multiple signaling pathways that have independent effects on
both actin and myosin which must be balanced appropriately to allow cell movement.
The pathways presented above, however, have been
pieced together from data obtained using a wide variety
of cell types subjected to a myriad of conditions and all
have been implicated in one way or another with metastasis of carcinoma cells. However, the signaling components that are considered important for these processes
vary substantially in the literature with certain pathways
being favored. One could effectively argue that distinctions in the signaling pathways utilized are a result of
variations in cell types or handling by investigators. However, they might also arise from differences in physiological conditions, which have not been systematically
evaluated.
Here, we dissect the pathways used by highly metastatic breast carcinoma cell line MDA-MB-231, which
are able to migrate and invade toward LPA, HGF and
EGF [17-19]. We find that partially overlapping subsets
of signaling pathways are employed by these cells depending on the environmental context. This observation
has important consequences for cancer therapy and rational drug design.

Methods
Cells treatments and reagents

The metastatic MDA-MB-231 breast carcinoma cell line
was cultured in low glucose DMEM (Invitrogen), 10%
Fetalplex (Gemini Bio-Products, West Sacramento CA),
1% penicillin-streptomycin, 1% L-glutamine (Invitrogen) to
70% confluence. For experiments, cells were trypsinized
and rinsed with DMEM plus 250 μg/ml fatty acid-free BSA
(Gemini Bio-Products cat# 700-107P) (DMEM/BSA). For
pharmacological inhibitor studies, cells were treated in
suspension for 30 min at 37°C with the following inhibitors: 10 μM ML-7 (MLCK inhibitor, Calbiochem
cat# 475880), 10 μM U0126 (MEK1/2 inhibitor, Calbiochem cat# 662005), 50 μM PD98059 (MEK1/2 inhibitor, Calbiochem cat# 513000), 10 μM Y-27632
(ROCK inhibitor Cayman Chemical cat# 10005583), or
100 μM NSC23766 (Rac inhibitor, Tocris Bioscience
cat#2161). To inhibit Rho directly with C3 exotransferase,
cells (3×106) were electroporated in serum-free DMEM
with 5 μg glutathione-S-transferase (GST; control) or
GST-C3 purified bacterial-expressed protein as done
previously [20,21] just prior to use.
Cell migration and invasion assays

For migration assays, transwell chambers were coated
with 15 μg/ml collagen I (BD Biosciences cat# 354249)
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as previously described [18]. For invasion assays, transwells were top-coated with 5 μg Matrigel (BD Biosciences cat# 354234), dried overnight, and rehydrated in
50 μl DMEM for 30 min at 37°C prior to assay; bottom
wells were coated with 15 μg/ml collagen I. Chemotaxis
or chemoinvasion was stimulated by adding to the bottom chamber 100 nM oleoyl-L-alpha-lysophosphatidic
acid sodium salt (LPA, Sigma cat# L-7269), 50 ng/ml
HGF (PeproTech cat# 100–39) or 5 ng/ml EGF (PeproTech cat# AF-100-15) diluted in DMEM/BSA, in the absence or presence of inhibitor. Cells (5×104) were allowed
to migrate or invade at 37°C for 3 hours in the presence of
inhibitors, as noted. Data are presented as the mean cell
number migrated per mm2 from triplicate wells and plotted with the standard deviation. Statistical significance
was calculated using a two-tailed unpaired t-test assuming
equal variances. For all experiments, data presented are
representative of a minimum of three independent assays.
In some cases, controls (cells not treated with chemoattractant or inhibitor) are reported more than once in a
figure if multiple conditions for the same experiment were
represented for consistency of the presentation.
MAPK, Rho and Rac activity assays

Cells were plated onto collagen-coated dishes for 3 hrs.
Cells were then treated with 10 μM U0126 or 50 μM
PD98059 before stimulation with 100 nM LPA, 50 ng/ml
HGF or 5 ng/ml EGF. The activity of the MAPK pathway
was determined by immunoblot analysis of p44/p42
MAPK (Erk 1/Erk2) for total Erk (3A7, mouse Ab, Cell
Signaling) and the phosphorylated form (197G2, rabbit
Ab, Cell Signaling).

Results
MLCK is involved in migration and invasion of MDA-MB-231
cells

For these studies, we utilized chemical inhibitors of select
signaling molecules (Figure 1) and performed short-term
(3 hrs) migration and invasion assays. This approach permits assessment of the immediate downstream impact of
select signaling pathways without substantially altering
transcription or proliferation that could affect our interpretation. Myosin activation by phosphorylation of the
MLC is essential for its interaction with actin and actinmyosin contractility. MLCK is the primary kinase that
controls MLC phosphorylation. To determine if MLCK
plays a central role in the migration and invasion of
MDA-MB-231 cells, we performed transwell migration assays and Matrigel invasion assays using LPA, HGF, or EGF
as chemoattractants in the presence of the MLCK inhibitor ML-7. As shown in Figure 2, there was a significant
decrease in the number of ML-7 treated cells that migrated or invaded compared to untreated cells, including
both basal and growth factor stimulated conditions. The
effect was stronger on invasion than migration with a
greater than 50% reduction in number of cells that were
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Rho assays were assessed using a Rhotekin RBD affinity assay as described previously [18,21,22]. For Rac assays, cells were serum starved overnight, treated with or
without 100 μM NSC23766 compound for 3 hrs and
then treated with chemoattractant as noted for 5 minutes
prior to harvesting. Cell lysates were then assessed for
Rac activity using a Pak1 Rac Binding Domain assay, as
we have performed previously [21,23].
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Figure 2 MLCK is required for cell migration and invasion in response to LPA, HGF and EGF. MDA-MB-231 cells were allowed to migrate
across a collagen-coated transwell (A) or invade through Matrigel (B) toward LPA, HGF or EGF for 3 hours in the presence or absence of the
MLCK inhibitor, ML-7 (inhib.), as noted. The numbers of cells migrated or invaded per mm2 were graphed with their standard deviations for
triplicate wells within a single experiment. For simplicity of presentation, statistically significant differences between stimulated and stimulated
plus inhibitor-treated cell conditions only were determined using a t-test (*p < 0.02). Data are representative of a minimum of three independent
assays for each condition.
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able to invade in the presence of inhibitor. Therefore,
these data demonstrate that MLCK is a key mediator of
both migration and invasion in response to a variety of
chemotactic agents for MDA-MB-231 cells.
MAPK pathway in migration and invasion of MDA-MB-231
cells

MAPK directly phosphorylates and activates MLCK, thus
facilitating the activation of myosin II in vitro [16]. To determine if MAPK influences chemotactic migration or invasion of MDA-MB-231 cells, we used two inhibitors of
MEK1 and MEK2, U0126 and PD98059, in migration and
invasion assays. We found inhibitor- and chemoattractant–specific effects for both migration and invasion. Both
inhibitors significantly reduced the number of cells that
migrated or invaded toward LPA (Figure 3). When HGF
was used to stimulate cells, U0126 did not affect either migration or invasion while the PD98059 inhibitor reduced
both; however, there was a trend toward inhibition with
the U0126. Neither inhibitor reduced migration toward
EGF while PD98059 was effective in reducing invasion of
these cells. The concentration of both of the inhibitors
used here were equally effective at reducing ERK phosphorylation, which reflects the MEK1/2 activity, in
these cells as analyzed by immunoblot (Additional file 1:
Figure S1). Further experiments were performed using
50 nM PD901, a more potent and specific MEK inhibitor.
These experiments gave the same results as the PD98059
compound for cell migration and for U0126 for invasion assays (data not shown). These data suggest that the MAPK
pathway acts to finely tune migration and invasion responses
to different stimuli, but is not required under all conditions.
Rac and Rho GTPase pathways in migration and invasion
of MDA-MB-231 cells

Rac and Rho are both major mediators of cell migration
and invasion, and are thought to have distinct functions in

Discussion and conclusions
The metastatic process requires cells to leave their native
site in response to environmental cues and move to a
different location where they proliferate to form new tumors. The cellular mechanisms used in this aberrant migratory response are fundamentally similar to those used
during normal developmental migration and boil down
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the migration and invasion of carcinoma cells [3,4]. Here,
we utilized electroporation of C3 protein (which ribosylates and inhibits RhoA, B and C; effectiveness shown in
Additional file 2: Figure S2) and the ROCK inhibitor
Y27632 to assess the Rho-ROCK pathway; Rac activation
was inhibited by NSC23766 [24]. We find that MDA-MB231 cells had opposing requirements for the Rho and Rac
pathways for cell migration. LPA–stimulated cells used
Rac but not Rho for migration (Figure 4). In fact, inhibition of Rho with C3 exotransferase and inhibition of
Rho’s downstream effector ROCK with Y-27632 tended to
increase migration (Figure 4A) suggesting that the Rho
pathway normally serves to limit this process in these
cells. In accordance with this concept, inhibition of the
Rho-ROCK pathway tended to increase membrane ruffling and lamellae formation in response to LPA (data not
shown). Notably, Rho/Rock pathway is essential to invasion in all conditions (Figure 4B and C) suggesting that
Rho is important mediator of tumor cell invasion. HGF
and EGF, in contrast, employ Rho but not Rac for migration. During invasion, however, both Rho and Rac pathways were necessary for EGF, while HGF required only
Rho. These data are summarized in Tables 1 and 2.
Notably, the Rac inhibitor, NSC23766 effectively blocked
Rac activation in response to all three chemoattractants
(Additional file 3: Figure S3). Therefore, these observations demonstrate that the chemoattractant and migration/invasion condition dictate which GTPases are
utilized.
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Figure 3 MAPK pathway has distinct effects on migration and invasion in response to LPA, HGF and EGF. MDA-MB-231 cells were treated
with one of two MEK1/2 inhibitors, U0126 or PD98059, and then assessed for either migration (A) or invasion (B) toward the indicated
chemoattractant. Cells migrated or invaded were then quantified, and results graphed as described in Figure 2. Data are representative of a
minimum of three independent assays for each condition. Statistically significant differences between stimulated and stimulated plus inhibitortreated cell conditions only were determined using a t-test (*p < 0.02).
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Figure 4 Rac and Rho GTPase inhibitors have differential effects on migration and invasion in response to LPA, HGF and EGF. MDA-MB231 cells were treated with inhibitors of the Rho pathway using C3 or Y-27632 (A, B, C), or the Rac pathway with NSC23766 (D, E) as described
in the Methods section, and assayed for their ability to migrate (A, D) or invade (B, C, E) toward various growth factors as described in Figure 2.
Data are representative of a minimum of three independent assays for each condition. Statistically significant differences between stimulated and
stimulated plus inhibitor-treated cell conditions only were determined using a t-test (*p < 0.02).
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Table 1 Summary of pathways used for growth
factor-stimulated migration
MLCK
Stimulus
LPA

YES

MAPK
(U0126)

(PD98059)

YES

YES

Rho

Rac

NO

YES

HGF

YES

NO

YES

YES

NO

EGF

YES

NO

NO

YES

NO

to the ability of the cell to organize its actin cytoskeleton
in a polarized manner and to activate the myosin motor
function to move that cytoskeleton in the direction of
polarization [25]. These basic functions can be mediated
by a variety of apparently redundant signaling pathways
that converge on the polymerization of actin and the activation state of the myosin II. However, we have shown
here that in a single cell type context specific motility
can signal through different subsets of pathways, as
summarized in Tables 1 and 2, despite the fact that they
all converge on the activity of a relatively small number
of proteins (see Figure 1). Not surprisingly, MLCK is an
essential player in both migration and invasion in response to all of the stimuli tested here, as it is central to
the control of myosin II phosphorylation and subsequent
activation. Beyond that, while capable of employing several pathways to drive actomyosin-mediated movement,
these cells utilize specific subsets of pathways to achieve
motility in different environments and toward distinct
growth factors. These observations demonstrate a surprising versatility and plasticity in carcinoma migration
and invasion.
In development and leukocyte navigation, it is well accepted that different chemoattractants will stimulate specific pathways such that patterning and precise navigation
can be achieved [26]. Certainly if all cells responded to a
stimulus in a similar manner, it would not be conducive to
precise navigation or organismal development. However,
the concept that tumor cells might utilize multiple growth
factor signaling pathways for dissemination in different
ways is not generally discussed. Rather the responses to
specific growth factors or cocktails of factors (such as
fibroblast conditioned medium) are reported in such a
way that these conditions likely apply to all cancer cells,

Table 2 Summary of pathways used for growth
factor-stimulated invasion
MLCK
Stimulus

MAPK

Rho

Rac

YES

YES

(U0126)

(PD98059)

YES

YES

YES

HGF

YES

NO*

YES

YES

NO

EGF

YES

NO

YES

YES

YES

LPA

*A trend toward inhibition is noted but does not reach statistical significance.

or at least a particular subtype of cancer. Furthermore,
modes of migration can vary substantially among tumor
cells [25,27]. Considerable attention has been given to the
role of the extracellular environment, its matrix composition, and matrix tension in mediating the differences in
cancer cell invasion. However, how select signaling events
from distinct growth factors and other chemoattractants
might facilitate these differences has received noticeably
less scrutiny. One exception is the roles of Rac and Rho
pathways. Rac is generally attributed to the formation of
lamellae, which are used to propel cells forward. These
large fan-shaped lamellae are advantageous for twodimensional migration but may in fact be inhibitory for
movement through a 3D environment where space is at a
premium, especially when matrix metalloprotease activity
is low [27]. In the 3D condition, a smaller pseudopodiallike protrusion might be more advantageous. Importantly,
RhoA has also been implicated in membrane ruffling and
lamellae formation [6,22,28] where it can play a major role
in 3D invasion [7,17,29,30]. Notably, the utilization of
RhoA in the formation of lamellae can be in cooperation
with [21] or independent from Rac1 [22]. The types of
protrusions formed by Rac, Rho or the cooperation of Rac
and Rho are expected to be functionally redundant, but
could in fact be fundamentally different in structure or
their function altered by the 3D environment. Certainly
more research is needed in this regard with careful attention to the fact that the role of these GTPases in invasion
may be multifaceted.
We further find that the MAPK pathway is an important mediator of LPA chemotaxis and invasion, but is dispensable for EGF-mediated migration. On the other
hand, the MAPK pathway plays a less definitive role in
the migration and invasion of these cells toward HGF.
The inconsistences observed in the migration and invasion behavior of MDA-MB-231 cells in response to different inhibitors of MEK, specifically in invasion toward
EGF and migration and invasion toward HGF, raises
some question as to how the MAPK pathway contributes to these events. While PD98059 and U0126 are
MEK1/2 inhibitors, these two inhibitors work by distinct
mechanisms. Furthermore, U0126 inhibits both MEK1
and MEK2 while PD98059 has a more potent effect on
MEK1 than on MEK2 [31,32]. The discrepancy in the results using the two inhibitors could indicate differences
in utilization of MEK1 versus MEK2, or that simply off
target effects of the inhibitors alter the interpretation.
Previous studies have noted similar differences between
the two compounds where PD98059 inhibits preferentially [33], thus suggesting MEK2 might counteract the
function of MEK1. Certainly more definitive experiments
will be required to fully elucidate the role of the MAPK
pathway, including substrate specificity and individual
contributions of each kinase.
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This study was not meant to be a comprehensive analysis of signaling pathways in response to the conditions
assessed here. But rather we sought to demonstrate that
migration of carcinoma cells, even a single cell line, is
more versatile than previously recognized. Here, we chose
to use pathway specific inhibitors and short term assays
rather than genetic analyses to distinguish the immediate
signaling effects of these pathways from the effects on
transcription or proliferation that might alter our interpretation of the results. Accordingly, our results do not
conclude, as an example, that Pak is unimportant to select
migration or invasion conditions where the Rac inhibitor
shows no effect. Pak could be stimulated by cdc42 or
Rac3, which are not reported targets of the Rac inhibitor
[24]. Notably, transcriptomes vary from cell to cell. And
with these variations come differences in how pathways
are activated, spatially localized, and utilized during specific signaling contexts. Since we use a single cell line for
this study, we find that a cell can use specific combinations of pathways to achieve migration or invasion in response to different stimuli that goes beyond cell-to-cell
variations in transcriptional profiles. The use of some but
not all of the possible pathways to control actin
reorganization has been seen in other cell types in response to particular environments. Clone A colon carcinoma cells use MAPK signaling (unpublished observation)
and Rho, but not Rac, to drive migration on laminin [22].
In contrast, MDA-MB-435 cells use Rac [23] and Rho [21]
but not MAPK (unpublished observation) to migrate toward LPA, which differs from the MDA-MB-231 cells.
To determine which signaling pathways govern the motility and invasion of a particular cell type, the physiological conditions including matrix composition, matrix
compliance, and growth factors utilized to stimulate these
processes need to be considered. This concept becomes
particularly important when screening genes and compounds for their impact on tumor invasion. As an example, fetal bovine serum (FBS) is a common stimulant
for migration and invasion assays. The major promigratory growth factor in FBS is LPA, which is found in
concentrations as high as 20 μM [34]. We have found previously that these high levels of LPA (1 μM and higher)
can actually inhibit the migration of breast carcinoma cells
[18]. In this study, we find that LPA does not require Rho
signaling for chemotaxis, but does for invasion. Therefore,
the use of FBS in migration or invasion would have low
potential to yield important insight into the breast cancer
invasion process. Furthermore, if screens utilize FBS in
migration assays to represent the tumor invasion process,
important compounds might be discarded in the in vitro
screening process, thus eliminating potentially effective
drugs in lieu of ones that ultimately may be ineffective
in vivo. Consequently, our study helps to highlight the importance of physiological context when assessing pertinent
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signal transduction pathways, which has notable implications for the effective development of cancer therapeutics
and rational drug design.

Additional files
Additional file 1: Figure S1. The Mek inhibitors U0126 and PD98059.
MDA-MB-231 cells were plated onto collagen coated dishes for 3 hrs and
then either left untreated or treated with 10 μM U0126 or 50 μM
PD98059 30 mins, as noted. Cells were then stimulated with 100 nM LPA,
50 ng/ml HGF, or 5 ng/ml EGF for 5 mins before lysis. Cell lysates were
then analyzed for phospho p44/p42 MAPK (Erk 1/2; upper bands) and
total p44/p42 MAPK by immunoblot analysis.
Additional file 2: Figure S2. Confirmation of C3 treatment on RhoA
inhibition. MDA-MB-231 cells were electroporated with bacterially
expressed GST or GST-C3, plated on collagen coated plates for 2 hrs and
then stimulated with 100 nM LPA for 5 mins. Cell lysates were then
analyzed for RhoA activity using a GST-Rhotekin RBD binding assay
(upper bands; active) and total RhoA (10% total; bottom bands) by
immunoblot analysis.
Additional file 3: Figure S3. NSC23766 effectively inhibits Rac in
response to LPA, HGF or EGF stimulation. MDA-MB-231 cells were serum
starved overnight and then treated with 100 μM of the Rac inhibitor
NSC23766 for 3 hours, as noted. Cell were then stimulated with BSA
(control), 100 nM LPA, 50 ng/ml HGF, or 5 ng/ml EGF for 5 mins. before
lysis. Cell lysates were then analyzed for Rac activity using a GST-Pak RBD
binding assay (upper bands; active) and total Rac (10% total; bottom
bands) by immunoblot analysis. Numbers below the blots represent fold
activity compared to untreated control cells.
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